With Sarepta’s Vyondys, US FDA Staff Saw Opportunity To Right Perceived Wrongs With Exondys
Executive Summary
ODE I director Ellis Unger chafed at the notion of approving the Duchenne muscular dystrophy drug golodirsen on the same unvalidated surrogate marker, this time in the face of infection and renal toxicity concerns; OND’s Peter Stein granted Sarepta’s appeal while also calling attention to the company’s failure to timely conduct the eteplirsen confirmatory trial.
You may also be interested in...
A Matter Of Precedent: US FDA Sometimes Labors Under Weight Of Unpopular Or Unfavorable Decisions
As agency observers wonder whether and how political considerations will impact the timing of a COVID-19 vaccine approval or authorization, the Pink Sheet looks at instances through the years where agency staffers found themselves operating under precedents with which they disagreed or that didn’t work out as expected.
Accelerated Approval: Avastin, Makena Bookend A Watershed Decade For US FDA’s Expedited Pathway
Pink Sheet interactive timeline looks at key regulatory, policy and legislative developments impacting the accelerated approval pathway over the last 10 years.
Vyondys 53 Clinical Development Timeline
Chronicle of the development and review of Sarepta’s golodirsen for treatment of Duchenne muscular dystrophy patients with a genetic mutation amenable to exon 53 skipping.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: